[1] FOLKMAN J. Tumor angiogenesis： therapeutic implications[J]. N Engl J Med， 1971， 285： 1182-1186.
[2] FOLKMAN J. Tumor angiogenesis[J]. Adv Cancer Res，1985，43：175-203.
[3] LI H， LU H， GRISEELLJ L， et al. Adenovirus mediated delivery of a uPA/uPAR antagonist suppressed angiogenesis-dependent tumor growth and dissemination in mice[J]. Gene Therapy， 1998， 5： 1105-1113.
[4] BROOKS P C， RICHARD A F C， CHERESH D A. Requirement of vascular integrin ανβ3 for angiogenesis[J]. Science，1994，264：569-571.
[5] PATAN S. Tie l and Tie 2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by mechanism of intussusceptive microvascular growth[J]. Microvasc Res，1998， 56：1-21.
[6] WONG A L，HARON Z A，WERNER S. Tie2 expression and phospharylation in angiogenic and quiscent adult tissues[J].Circ Res，1997，81： 567-574.
[7] HANAHAN D. Signaling vascular morphogenesis and maintenance[J].Science，1997， 277(5322)：48-50.
[8] YANCOPOULOS G D，KLAGSBRUN M， FOLKMAN J. Vasculogenesis， angiogenesis， and growth factors： ephrins enter the fray at the border[J]．Cell， 1998， 93： 661-664.
[9] SCHWEIGERER L，NEUFELD G，FRIEDMAN J. Capillary endothelial cells express basic fibroblast growth factor， a mitogen that promotes their own growth[J]. Nature，1987， 325：257.
[10] FERRARA N, DAVIS S T. The biology of vascular endothelial growth factor[J]. Endoc Rev，1997， 18(1)： 4-25.
[11] BROWN L F， BERSE B， JACKMAN R W， et al. Expression of vascular permeability factor(vascular endothelial growth factor) and its receptors in adenccarcinoma of gastrointestinal tract[J]. Cancer Res， 1993， 53： 4727-4735.
[12] BREKKEN R A, OVCRHOLSER J E， STASMY V A， et al. Selective inhibitionofvascular endothelial growthfactor(VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growthinmice[J]. Cancer Res，2000，60： 5117-5124.
[13] PATAN S. Tie l and Tie 2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by mechanism of intussusceptive microvascular growth[J]. Microvasc Res，1998， 56：1-21.
[14] BROOKS P， MONTGOMERY A， ROSENFELD M， et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels[J]. Cell， 1994， 79(7)：1157-1164.
[15] BROOKS P C， SILLETTI S， VON SCHALSCHA T L， et al. Disruption of angiogenesis by PEX， a noncatalytic metalloproteinase fragment with integrin binding activity[J]. Cell， 1998，92(3)：391-400.
[16] VAN HENSBERGEN Y， BROXTERMAN H J， HANEMAAIJER R， et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid[J]. Clin Cancer Res， 2002， 8(12)： 3747-3754.
[17] XIONG X B， HUANG Y， LU W L， et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy： in vitro and in vivo[J]. J Pharm Sci， 2005， 94（8）： 1782-1793.
[18] XIONG X B， HUANG Y， LU W L， et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic[J]. J Controlled Release， 2005， 107（2）： 262-275.
[19] ZHAO H， WANG J C， SUN Q S. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted withhuman ovarian cancer[J]. J Drug Target， 2009， 17(1)：10-18.
[20] ABRA R M， BANKERT R B， CHEN F， et al. The next generation of liposome delivery systems： recent experience with tumor-targeted， sterically-stabilized immunoliposomes and active-loading gradients[J]. J Liposome Res，2002，12(1-2)：1-3.
[21] SCHIFFELERS R M， KONING G A， TEN HAGEN T L， et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin[J]. J Controlled Release， 2003， 91(1-2)：115-122.
[22] DAI W， YANG T， WANG X， et al. PHSCNK-Modified anddoxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells[J]. J Drug Target， 2010， 18(4)：254-263.
[23] ZHANG Y F， WANG J C， BIAN D Y， et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy： in vitro and in vivo studies[J]. Eur J Pharm Biopharm， 2010，74(3)：467-473.
[24] PATTILLO C B， SARI-SARRAF F， NALLAMOTHU R， et al. Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay[J]. Pharm Res， 2005， 22（7）：1117-1120.
[25] JIANG J， YANG S J， WANG J C， et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin[J]. Eur J Pharm Biopharm， 2010， 76（2）：170-178.
[26] BIBBY D C， TALMADGE J E， DALAL M K， et al. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice[J]. Int J Pharm，2005， 293(1-2)：281-290.
[27] DANHIER F， VROMAN B， LECOUTURIER N， et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel[J]. J Controlled Release，2009， 140(2)：166-173.
[28] CHEN K， XIE J， XU H， et al. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting[J]. Biomaterials， 2009， 30(36)：6912-6919.
[29] XIONG X B， MAHMUD A， ULUDAG H， et al. Conjugation of arginine-glycine-aspartic acid peptides to poly (ethylene oxide)-b-poly (ε-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells[J]. Biomacromolecules， 2007， 8（3）：874-884.
[30] WOODLE M C， SCARIA P， GANESHB S， et al. Sterically stabilized polyplex： ligand mediated activity[J]. J Controlled Release， 2001， 74（1-3）：309-311.
[31] NASONGKLA N， SHUAI X T， AI H， et al. cRGD-Functionalized polymer micelles for targeted doxorubicin delivery[J]. Angew Chem Int Edit， 2004，43（46）：6323-6327.
[32] NASONGKLA N， BEY E， REN J M， et al. Multifunctional polymeric micelles as cencer-targeted， MRI-ultrasensitive drug delivery systems[J]. Nano Lett， 2006，6：2427-2430.
[33] ZHAN C， GU B， XIE C， et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect[J]. J Controlled Release， 2010，143(1)：136-42.
[34] ARAP W， PASQUALINI R， RUOSLAHTI E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model[J]. Science， 1998，279（5349）：377-380.
[35] SCHRAA A J， KOK R J， BERENDSEN A D， et al. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting[J]. J Controlled Release，2002，83(2)：241-251.
[36] LINE B R， MITRA A， NAN A， et al. Targeting tumor angiogenesis：comparison of peptide and polymer-peptide conjugates[J]. J Nucl Med， 2005，46(9)：1552-1560.
[37] JANSSEN A P， SCHIFFELERS R M， TEN HAGEN T L， et al. Peptide-targeted PEG-liposomes in anti-angiogenic therapy[J]. Int J Pharm，2003，254(1)：55-58.
[38] GAO Y， CHEN L， GU W， et al. Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model[J]. Mo Pharmaceutics，2008，5 (6)：1044-1054.
[39] YU D H， LU Q， XIE J， et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature[J]. Biomaterials，2010，31(8)：2278-2292.
[40] ARAP W， PASQUALINI R， RUOSLAHTI E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model[J]. Science，1998， 279(5349)： 377-380.
[41] MAJHEN D， GABRILOVAC J， ELOIT M， et al. Disulfide bond formation in NGR fiber-modified adenovirus is essential for retargeting to aminopeptidase N [J]. Biochem Biophys Res Commun， 2006，348(1)： 278-287.
[42] ELLERBY H M， ARAP W， ELLERBY L M， et al. Anti-cancer activity of targeted pro-apoptotic peptides [J]. Nat Med， 1999， 5(9)： 1032-1038.
[43] CURNIS F， SACCHI A， BORGNA L， et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) [J]. Nat Biotechnol，2000， 18(11)： 1185-1190.
[44] WANG X， WANG Y， CHEN X， et al. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells[J]. J Controlled Release， 2009， 139(1)：56-62.
[45] NEGUSSIE A H， MILLER J L， REDDY G， et al. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome[J]. J Controlled Release， 2010， 143(2)：265-273.
[46] MAI J， SONG S， RUI M，et al. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells [J]. J Controlled Release， 2009， 139(3)：174-181.
[47] CHEN X， WANG X， WANG Y， et al. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide[J]. J Controlled Release， 2010， 145(1)：17-25.
[48] HATAKEYAMA H， AKITA H， ISHIDA E， et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes[J]. Int J Pharm， 2007，342(1-2)：194-200.
[49] JAIN R K. Normalization of tumor vaculature： an emerging concept in antiangiogenic therapy[J]. Science， 2005， 307（5706）： 58- 62.